Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy

Journal of Interferon and Cytokine Research

Volumn 35, Issue 8, 2015, Pages 585-599

  Bhattacharya, Palash ^a   Budnick, Isadore ^a   Singh, Medha ^a   Thiruppathi, Muthusamy ^a   Alharshawi, Khaled ^a   Elshabrawy, Hatem ^a   Holterman, Mark J ^a   Prabhakar, Bellur S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HUMAN MONOCLONAL ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 4; MAVRILIMUMAB; SIPULEUCEL T; TUMOR VACCINE; ANTIINFLAMMATORY AGENT; AUTACOID; IMMUNOSUPPRESSIVE AGENT;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DIFFERENTIATION; COLON CANCER; CROHN DISEASE; DENDRITIC CELL; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATION; KIDNEY CARCINOMA; LUNG CARCINOMA; MELANOMA; MYASTHENIA GRAVIS; NEOPLASM; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; ANIMAL; AUTOIMMUNE DISEASES; GENETICS; METABOLISM; PHYSIOLOGY; PRECLINICAL STUDY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; CYTOKINES; DRUG EVALUATION, PRECLINICAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INFLAMMATION; INFLAMMATION MEDIATORS;

EID: 84932168247     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0149     Document Type: Review

References (187)

1. Alsalameh S, Firestein GS, Oez S, Kurrle R, Kalden JR, Burmester GR. 1994. Regulation of granulocyte macrophage colony stimulating factor production by human articular chondrocytes. Induction by both tumor necrosis factor-alpha and interleukin 1, downregulation by transforming growth factor beta and upregulation by fibroblast growth factor. J Rheumatol 21(6):993-1002.
2. Anastasi E, Campese AF, Bellavia D, Bulotta A, Balestri A, Pascucci M, Checquolo S, Gradini R, Lendahl U, Frati L, Gulino A, Di Mario U, Screpanti I. 2003. Expression of activated Notch3 in transgenic mice enhances generation of T regulatory cells and protects against experimental autoimmune diabetes. J Immunol 171(9):4504-4511.
3. Armstrong CA, Botella R, Galloway TH, Murray N, Kramp JM, Song IS, Ansel JC. 1996. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res 56(9):2191-2198.
4. Baldwin GC, Gasson JC, Kaufman SE, Quan SG, Williams RE, Avalos BR, Gazdar AF, Golde DW, DiPersio JF. 1989. Nonhematopoietic tumor cells express functional GM-CSF receptors. Blood 73(4):1033-1037.
5. Begley CG, Lopez AF, Nicola NA, Warren DJ, Vadas MA, Sanderson CJ, Metcalf D. 1986. Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors. Blood 68(1):162-166.
6. Behrens F, Tak PP, Ostergaard M, Stoilov R, Wiland P, Huizinga TW, Berenfus VY, Vladeva S, Rech J, Rubbert-Roth A, Korkosz M, Rekalov D, Zupanets IA, Ejbjerg BJ, Geiseler J, Fresenius J, Korolkiewicz RP, Schottelius AJ, Burkhardt H. 2014. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis [Epub ahead of print]; DOI: 10.1136/annrheumdis-2013-204816.
7. Bendandi M. 2009. Idiotype vaccines for lymphoma: proof-ofprinciples and clinical trial failures. Nat Rev Cancer 9(9): 675-681.
8. Benwell RK, Lee DR. 2010. Essential and synergistic roles of IL1 and IL6 in human Th17 differentiation directed by TLR ligand-activated dendritic cells. Clin Immunol 134(2):178-187.
9. Berdel WE, Danhauser-Riedl S, Steinhauser G, Rastetter J. 1990. Stimulation of clonal growth of human colorectal tumor cells by IL-3 and GM-CSF. Modulation of 5-FU cytotoxicity by GM-CSF. Onkologie 13(6):437-443.
10. Berenbaum F, Rajzbaum G, Amor B, Toubert A. 1994. Evidence for GM-CSF receptor expression in synovial tissue. An analysis by semi-quantitative polymerase chain reaction on rheumatoid arthritis and osteoarthritis synovial biopsies. Eur Cytokine Netw 5(1):43-46.
11. Berger TG, Schulze-Koops H, Schafer M, Muller E, Lutz MB. 2009. Immature and maturation-resistant human dendritic cells generated from bone marrow require two stimulations to induce T cell anergy in vitro. PLoS One 4(8):e6645.
12. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090):235-238.
13. Bhattacharya P, Gopisetty A, Ganesh BB, Sheng JR, Prabhakar BS. 2011. GM-CSF-induced, bone-marrow-derived dendritic cells can expand natural Tregs and induce adaptive Tregs by different mechanisms. J Leukoc Biol 89(2):235-249.
14. Bischof RJ, Zafiropoulos D, Hamilton JA, Campbell IK. 2000. Exacerbation of acute inflammatory arthritis by the colonystimulating factors CSF-1 and granulocyte macrophage (GM)-CSF: evidence of macrophage infiltration and local proliferation. Clin Exp Immunol 119(2):361-367.
15. Bogdan C, Vodovotz Y, Nathan C. 1991. Macrophage deactivation by interleukin 10. J Exp Med 174(6):1549-1555.
16. Brizzi MF, Avanzi GC, Veglia F, Clark SC, Pegoraro L. 1990. Expression and modulation of IL-3 and GM-CSF receptors in human growth factor dependent leukaemic cells. Br J Haematol 76(2):203-209.
17. Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, Restifo NP. 1999. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8 + T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 162(10):5728-5737.
18. Broughton SE, Dhagat U, Hercus TR, Nero TL, Grimbaldeston MA, Bonder CS, Lopez AF, Parker MW. 2012. The GMCSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol Rev 250(1): 277-302.
19. Burgess AW, Camakaris J, Metcalf D. 1977. Purification and properties of colony-stimulating factor from mouse lungconditioned medium. J Biol Chem 252(6):1998-2003.
20. Burmester GR, Feist E, Sleeman MA, Wang B, White B, Magrini F. 2011. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-alpha, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis 70(9):1542-1549.
21. Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, Szombati I, Esfandiari E, Sleeman MA, Kane CD, Cavet G, Wang B, Godwood A, Magrini F, Group ES. 2013. Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 72(9):1445-1452.
22. Campbell IK, Bendele A, Smith DA, Hamilton JA. 1997. Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann Rheum Dis 56(6):364-368.
23. Campbell IK, Rich MJ, Bischof RJ, Dunn AR, Grail D, Hamilton JA. 1998. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol 161(7):3639-3644.
24. Candido J, Hagemann T. 2013. Cancer-related inflammation. J Clin Immunol 33 (Suppl. 1):S79-S84.
25. Cannistra SA, Groshek P, Garlick R, Miller J, Griffin JD. 1990. Regulation of surface expression of the granulocyte/macrophage colony-stimulating factor receptor in normal human myeloid cells. Proc Natl Acad Sci U S A 87(1):93-97.
26. Cebon J, Nicola N, Ward M, Gardner I, Dempsey P, Layton J, Duhrsen U, Burgess AW, Nice E, Morstyn G. 1990. Granulocyte-macrophage colony stimulating factor from human lymphocytes. The effect of glycosylation on receptor binding and biological activity. J Biol Chem 265(8):4483-4491.
27. Chang GC, Lan HC, Juang SH, Wu YC, Lee HC, Hung YM, Yang HY, Whang-Peng J, Liu KJ. 2005. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer 103(4):763-771.
28. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT, Bruning JC, Muller W, Rudensky AY. 2011. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34(4):566-578.
29. Cheatem D, Ganesh BB, Gangi E, Vasu C, Prabhakar BS. 2009. Modulation of dendritic cells using granulocyte-macrophage colony-stimulating factor (GM-CSF) delays type 1 diabetes by enhancing CD4 + CD25 + regulatory T cell function. Clin Immunol 131(2):260-270.
30. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. 2003. Conversion of peripheral CD4 + CD25-naive T cells to CD4 + CD25 + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198(12):1875-1886.
31. Chiba S, Tojo A, Kitamura T, Urabe A, Miyazono K, Takaku F. 1990. Characterization and molecular features of the cell surface receptor for human granulocyte-macrophage colonystimulating factor. Leukemia 4(1):29-36.
32. Codarri L, Gyulveszi G, Tosevski V, Hesske L, Fontana A, Magnenat L, Suter T, Becher B. 2011. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 12(6):560-567.
33. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A. 1992. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80(8):2012-2020.
34. Comalada M, Xaus J, Sanchez E, Valledor AF, Celada A. 2004. Macrophage colony-stimulating factor-, granulocyte-macrophage colony-stimulating factor-, or IL-3-dependent survival of macrophages, but not proliferation, requires the expression of p21(Waf1) through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol 34(8):2257-2267.
35. Cook AD, Braine EL, Campbell IK, Rich MJ, Hamilton JA. 2001. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res 3(5):293-298.
36. Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IP. 2009. G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 5(10):554-559.
37. Costabel U, Guzman J. 2005. Pulmonary alveolar proteinosis: a new autoimmune disease. Sarcoidosis Vasc Diffuse Lung Dis 22 (Suppl. 1):S67-S73.
38. Dabritz J, Bonkowski E, Chalk C, Trapnell BC, Langhorst J, Denson LA, Foell D. 2013. Granulocyte macrophage colonystimulating factor auto-antibodies and disease relapse in inflammatory bowel disease. Am J Gastroenterol 108(12): 1901-1910.
39. Dedhar S, Gaboury L, Galloway P, Eaves C. 1988. Human granulocyte-macrophage colony-stimulating factor is a growth factor active on a variety of cell types of nonhemopoietic origin. Proc Natl Acad Sci U S A 85(23):9253-9257.
40. Dieckgraefe BK, Korzenik JR. 2002. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 360(9344):1478-1480.
41. Di Gregoli K, Johnson JL. 2012. Role of colony-stimulating factors in atherosclerosis. Curr Opin Lipidol 23(5):412-421.
42. Dinarello CA. 2011. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117(14):3720-3732.
43. Dominguez PM, Lopez-Bravo M, Kalinke U, Ardavin C. 2011. Statins inhibit iNOS-mediated microbicidal potential of activated monocyte-derived dendritic cells by an IFN-betadependent mechanism. Eur J Immunol 41(11):3330-3339.
44. Dranoff G. 2002. GM-CSF-based cancer vaccines. Immunol Rev 188:147-154.
45. Dranoff G. 2003. GM-CSF-secreting melanoma vaccines. Oncogene 22(20):3188-3192.
46. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90(8): 3539-3543.
47. Ebner K, Bandion A, Binder BR, de Martin R, Schmid JA. 2003. GMCSF activates NF-kappaB via direct interaction of the GMCSF receptor with IkappaB kinase beta. Blood 102(1):192-199.
48. Eggermont AM. 2009. Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Clin Cancer Res 15(22): 6745-6747.
49. El-Behi M, Ciric B, Dai H, Yan Y, Cullimore M, Safavi F, Zhang GX, Dittel BN, Rostami A. 2011. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 12(6):568-575.
50. Eroglu Z, Kong KM, Jakowatz JG, Samlowski W, Fruehauf JP. 2011. Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. Cancer Chemother Pharmacol 68(4):1081-1087.
51. Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL. 2009. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res 15(22):7029-7035.
52. Fiehn C, Wermann M, Pezzutto A, Hufner M, Heilig B. 1992. [Plasma GM-CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy]. Z Rheumatol 51(3):121-126.
53. Fischer HG, Reichmann G. 2001. Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol 166(4):2717-2726.
54. Fleetwood AJ, Cook AD, Hamilton JA. 2005. Functions of granulocyte-macrophage colony-stimulating factor. Crit Rev Immunol 25(5):405-428.
55. Forni G, Fujiwara H, Martino F, Hamaoka T, Jemma C, Caretto P, Giovarelli M. 1988. Helper strategy in tumor immunology: expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapy. Cancer Metastasis Rev 7(4):289-309.
56. Forni G, Giovarelli M, Santoni A. 1985. Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumorbearing mice to inhibit tumor growth. J Immunol 134(2): 1305-1311.
57. Francisco-Cruz A, Aguilar-Santelises M, Ramos-Espinosa O, Mata-Espinosa D, Marquina-Castillo B, Barrios-Payan J, Hernandez-Pando R. 2014. Granulocyte-macrophage colonystimulating factor: not just another haematopoietic growth factor. Med Oncol 31(1):774.
58. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, Bicciato S, Bronte V. 2006. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8 + T cells. J Clin Invest 116(10):2777-2790.
59. Ganesh BB, Bhattacharya P, Gopisetty A, Sheng J, Vasu C, Prabhakar BS. 2011. IL-1beta promotes TGF-beta1 and IL-2 dependent Foxp3 expression in regulatory T cells. PLoS One 6(7):e21949.
60. Ganesh BB, Cheatem DM, Sheng JR, Vasu C, Prabhakar BS. 2009. GM-CSF-induced CD11c + CD8a-dendritic cells facilitate Foxp3 + and IL-10 + regulatory T cell expansion resulting in suppression of autoimmune thyroiditis. Int Immunol 21(3):269-282.
61. Gangi E, Vasu C, Cheatem D, Prabhakar BS. 2005. IL-10-producing CD4 + CD25 + regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factorinduced suppression of experimental autoimmune thyroiditis. J Immunol 174(11):7006-7013.
62. Gearing DP, King JA, Gough NM, Nicola NA. 1989. Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor. EMBO J 8(12):3667-3676.
63. Gilliet M, Boonstra A, Paturel C, Antonenko S, Xu XL, Trinchieri G, O'Garra A, Liu YJ. 2002. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med 195(7): 953-958.
64. Go NF, Castle BE, Barrett R, Kastelein R, Dang W, Mosmann TR, Moore KW, Howard M. 1990. Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosomelinked immunodeficiency B cells. J Exp Med 172(6):1625-1631.
65. Gopisetty A, Bhattacharya P, Haddad C, Bruno JC, Jr., Vasu C, Miele L, Prabhakar BS. 2013. OX40L/Jagged1 cosignaling by GM-CSF-induced bone marrow-derived dendritic cells is required for the expansion of functional regulatory T cells. J Immunol 190(11):5516-5525.
66. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, Cagnard N, Carpentier W, Tang Q, Bluestone J, Chatenoud L, Klatzmann D, Salomon BL, Piaggio E. 2010. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 207(9):1871-1878.
67. Guindi C, Menard M, Cloutier A, Gaudreau S, Besin G, Larivee P, McDonald PP, Dupuis G, Amrani A. 2012. Differential role of NF-kappaB, ERK1/2 and AP-1 in modulating the immunoregulatory functions of bone marrow-derived dendritic cells from NOD mice. Cell Immunol 272(2):259-268.
68. Guthridge MA, Barry EF, Felquer FA, McClure BJ, Stomski FC, Ramshaw H, Lopez AF. 2004. The phosphoserine-585-dependent pathway of the GM-CSF/IL-3/IL-5 receptors mediates hematopoietic cell survival through activation of NF-kappaB and induction of bcl-2. Blood 103(3):820-827.
69. Guthridge MA, Powell JA, Barry EF, Stomski FC, McClure BJ, Ramshaw H, Felquer FA, Dottore M, Thomas DT, To B, Begley CG, Lopez AF. 2006. Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO J 25(3):479-489.
70. Hamilton JA. 2002. GM-CSF in inflammation and autoimmunity. Trends Immunol 23(8):403-408.
71. Hamilton JA. 2008. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 8(7):533-544.
72. Hamilton JA, Stanley ER, Burgess AW, Shadduck RK. 1980. Stimulation of macrophage plasminogen activator activity by colony-stimulating factors. J Cell Physiol 103(3):435-445.
73. Hansen G, Hercus TR, McClure BJ, Stomski FC, Dottore M, Powell J, Ramshaw H, Woodcock JM, Xu Y, Guthridge M, McKinstry WJ, Lopez AF, Parker MW. 2008. The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell 134(3):496-507.
74. Hara T, Miyajima A. 1992. Two distinct functional high affinity receptors for mouse interleukin-3 (IL-3). EMBO J 11(5): 1875-1884.
75. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, Ravetch JV, Steinman RM, Nussenzweig MC. 2001. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 194(6):769-779.
76. Hayashida K, Kitamura T, Gorman DM, Arai K, Yokota T, Miyajima A. 1990. Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colonystimulating factor (GM-CSF): reconstitution of a high-affinity GM-CSF receptor. Proc Natl Acad Sci U S A 87(24):9655-9659.
77. Hercus TR, Dhagat U, Kan WL, Broughton SE, Nero TL, Perugini M, Sandow JJ, D'Andrea RJ, Ekert PG, Hughes T, Parker MW, Lopez AF. 2013. Signalling by the betac family of cytokines. Cytokine Growth Factor Rev 24(3):189-201.
78. Hercus TR, Thomas D, Guthridge MA, Ekert PG, King-Scott J, Parker MW, Lopez AF. 2009. The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood 114(7): 1289-1298.
79. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. 2009. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16):3670-3679.
80. Hillyer L, Dao B, Niemiec P, Lee S, Doidge M, Bemben I, Neyestani T, Woodward B. 2006. Elevated bioactivity of the tolerogenic cytokines, interleukin-10 and transforming growth factor-beta, in the blood of acutely malnourished weanling mice. Exp Biol Med (Maywood) 231(8):1439-1447.
81. Holtl L, Rieser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M. 1999. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 161(3):777-782.
82. Hutchins NA, Unsinger J, Hotchkiss RS, Ayala A. 2014. The new normal: immunomodulatory agents against sepsis immune suppression. Trends Mol Med 20(4):224-233.
83. Inaba K, Turley S, Iyoda T, Yamaide F, Shimoyama S, Reis e Sousa C, Germain RN, Mellman I, Steinman RM. 2000. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med 191(6):927-936.
84. Inaba K, Witmer-Pack M, Inaba M, Hathcock KS, Sakuta H, Azuma M, Yagita H, Okumura K, Linsley PS, Ikehara S, Muramatsu S, Hodes RJ, Steinman RM. 1994. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 180(5):1849-1860.
85. Ivanov, II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. 2006. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17 + T helper cells. Cell 126(6):1121-1133.
86. Kang Z, Wang C, Zepp J, Wu L, Sun K, Zhao J, Chandrasekharan U, DiCorleto PE, Trapp BD, Ransohoff RM, Li X. 2013. Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2 + glial cells. Nat Neurosci 16(10):1401-1408.
87. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, Investigators IS. 2010. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363(5):411-422.
88. Kaufman HL, Ruby CE, Hughes T, Slingluff CL, Jr. 2014. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer 2:11.
89. Kaushansky K, O'Hara PJ, Hart CE, Forstrom JW, Hagen FS. 1987. Role of carbohydrate in the function of human granulocyte-macrophage colony-stimulating factor. Biochemistry 26(15):4861-4867.
90. Kelsen JR, Rosh J, Heyman M, Winter HS, Ferry G, Cohen S, Mamula P, Baldassano RN. 2010. Phase I trial of sargramostim in pediatric Crohn's disease. Inflamm Bowel Dis 16(7):1203-1208.
91. Kelso A, Metcalf D. 1985. Clonal heterogeneity in colony stimulating factor production by murine T lymphocytes. J Cell Physiol 123(1):101-110.
92. Kim SH, Yang EM, Park HJ, Ye YM, Lee HY, Park HS. 2007. Differential contribution of the CysLTR1 gene in patients with aspirin hypersensitivity. J Clin Immunol 27(6):613-619.
93. Ko HJ, Brady JL, Ryg-Cornejo V, Hansen DS, Vremec D, Shortman K, Zhan Y, Lew AM. 2014. GM-CSF-responsive monocyte-derived dendritic cells are pivotal in Th17 pathogenesis. J Immunol 192(5):2202-2209.
94. Koch F, Stanzl U, Jennewein P, Janke K, Heufler C, Kampgen E, Romani N, Schuler G. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 184(2):741-746.
95. Kohanbash G, McKaveney K, Sakaki M, Ueda R, Mintz AH, Amankulor N, Fujita M, Ohlfest JR, Okada H. 2013. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptoralpha. Cancer Res 73(21):6413-6423.
96. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP, 3rd, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ. 2011. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 365(22):2055-2066.
97. Korn T, Anderson AC, Bettelli E, Oukka M. 2007. The dynamics of effector T cells and Foxp3 + regulatory T cells in the promotion and regulation of autoimmune encephalomyelitis. J Neuroimmunol 191(1-2):51-60.
98. Kriegel MA, Rathinam C, Flavell RA. 2012. Pancreatic islet expression of chemokine CCL2 suppresses autoimmune diabetes via tolerogenic CD11c + CD11b + dendritic cells. Proc Natl Acad Sci U S A 109(9):3457-3462.
99. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM. 2008. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 205(7):1535-1541.
100. Lari R, Fleetwood AJ, Kitchener PD, Cook AD, Pavasovic D, Hertzog PJ, Hamilton JA. 2007. Macrophage lineage phenotypes and osteoclastogenesis-complexity in the control by GM-CSF and TGF-beta. Bone 40(2):323-336.
101. Lassi K, Dawson NA. 2010. Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol 22(3):263-267.
102. Li G, Kim YJ, Broxmeyer HE. 2005. Macrophage colonystimulating factor drives cord blood monocyte differentiation into IL-10(high)IL-12absent dendritic cells with tolerogenic potential. J Immunol 174(8):4706-4717.
103. Li MO, Wan YY, Flavell RA. 2007. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 26(5): 579-591.
104. Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet JC, Alarcon-Segovia D, Galanaud P, Emilie D. 1995. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 181(3):839-844.
105. Lopez AF, Eglinton JM, Gillis D, Park LS, Clark S, Vadas MA. 1989. Reciprocal inhibition of binding between interleukin 3 and granulocyte-macrophage colony-stimulating factor to human eosinophils. Proc Natl Acad Sci U S A 86(18):7022-7026.
106. Lutz MB, Suri RM, Niimi M, Ogilvie AL, Kukutsch NA, Rossner S, Schuler G, Austyn JM. 2000. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 30(7):1813-1822.
107. Maddur MS, Miossec P, Kaveri SV, Bayry J. 2012. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 181(1):8-18.
108. Manel N, Unutmaz D, Littman DR. 2008. The differentiation of human T(H)-17 cells requires transforming growth factorbeta and induction of the nuclear receptor RORgammat. Nat Immunol 9(6):641-649.
109. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. 2004. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25(12): 677-686.
110. Marlow N, Morris T, Brocklehurst P, Carr R, Cowan FM, Patel N, Petrou S, Redshaw ME, Modi N, Dore C. 2013. A randomised trial of granulocyte-macrophage colony-stimulating factor for neonatal sepsis: outcomes at 2 years. Arch Dis Child Fetal Neonatal Ed 98(1):F46-F53.
111. Mausberg AK, Jander S, Reichmann G. 2009. Intracerebral granulocyte-macrophage colony-stimulating factor induces functionally competent dendritic cells in the mouse brain. Glia 57(12):1341-1350.
112. Mayer CT, Berod L, Sparwasser T. 2012. Layers of dendritic cell-mediated T cell tolerance, their regulation and the prevention of autoimmunity. Front Immunol 3:183.
113. McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, McClanahan TK, O'Shea JJ, Cua DJ. 2009. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 10(3):314-324.
114. McQualter JL, Darwiche R, Ewing C, Onuki M, Kay TW, Hamilton JA, Reid HH, Bernard CC. 2001. Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med 194(7): 873-882.
115. Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, Reinke P, Volk HD. 2009. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 180(7): 640-648.
116. Meriggioli MN, Sheng JR, Li L, Prabhakar BS. 2008. Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis. Ann N Y Acad Sci 1132:276-282.
117. Metcalf D. 1980. Clonal analysis of proliferation and differentiation of paired daughter cells: action of granulocyte-macrophage colony-stimulating factor on granulocyte-macrophage precursors. Proc Natl Acad Sci U S A 77(9): 5327-5330.
118. Metcalf D. 1988. Colony stimulating factors and hemopoiesis. Ann Acad Med Singapore 17(2):166-170.
119. Metcalf D. 2010. The colony-stimulating factors and cancer. Nat Rev Cancer 10(6):425-434.
120. Metcalf D, Merchav S. 1982. Effects of GM-CSF deprivation on precursors of granulocytes and macrophages. J Cell Physiol 112(3):411-418.
121. Metcalf D, Moore JG. 1988. Divergent disease patterns in granulocyte-macrophage colony-stimulating factor transgenic mice associated with different transgene insertion sites. Proc Natl Acad Sci U S A 85(20):7767-7771.
122. Miller G, Pillarisetty VG, Shah AB, Lahrs S, Xing Z, DeMatteo RP. 2002. Endogenous granulocyte-macrophage colonystimulating factor overexpression in vivo results in the longterm recruitment of a distinct dendritic cell population with enhanced immunostimulatory function. J Immunol 169(6): 2875-2885.
123. Min L, Mohammad Isa SA, Shuai W, Piang CB, Nih FW, Kotaka M, Ruedl C. 2010. Cutting edge: granulocyte-macrophage colony-stimulating factor is the major CD8 + T cell-derived licensing factor for dendritic cell activation. J Immunol 184(9): 4625-4629.
124. Mucida D, Pino-Lagos K, Kim G, Nowak E, Benson MJ, Kronenberg M, Noelle RJ, Cheroutre H. 2009. Retinoic acid can directly promote TGF-beta-mediated Foxp3(+) Treg cell conversion of naive T cells. Immunity 30(4):471-472; author reply 472-473.
125. Mueller MM, Herold-Mende CC, Riede D, Lange M, Steiner HH, Fusenig NE. 1999. Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am J Pathol 155(5):1557-1567.
126. Muls N, Jnaoui K, Dang HA, Wauters A, Van Snick J, Sindic CJ, van Pesch V. 2012. Upregulation of IL-17, but not of IL- 9, in circulating cells of CIS and relapsing MS patients. Impact of corticosteroid therapy on the cytokine network. J Neuroimmunol 243(1-2):73-80.
127. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. 1996. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29(6):371-380.
128. Naik SH, Metcalf D, van Nieuwenhuijze A, Wicks I, Wu L, O'Keeffe M, Shortman K. 2006. Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat Immunol 7(6):663-671.
129. Nemunaitis J, Sterman D, Jablons D, Smith JW, 2nd, Fox B, Maples P, Hamilton S, Borellini F, Lin A, Morali S, Hege K. 2004. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 96(4):326-331.
130. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4(3):328-332.
131. Ogawa Y, Duru EA, Ameredes BT. 2008. Role of IL-10 in the resolution of airway inflammation. Curr Mol Med 8(5): 437-445.
132. Ohashi K, Sato A, Takada T, Arai T, Kasahara Y, Hojo M, Nei T, Nakayama H, Motoi N, Urano S, Eda R, Yokoba M, Tsuchihashi Y, Nasuhara Y, Ishii H, Ebina M, Yamaguchi E, Inoue Y, Nakata K, Tazawa R. 2012. Reduced GM-CSF autoantibody in improved lung of autoimmune pulmonary alveolar proteinosis. Eur Respir J 39(3):777-780.
133. Park LS, Martin U, Sorensen R, Luhr S, Morrissey PJ, Cosman D, Larsen A. 1992. Cloning of the low-affinity murine granulocyte-macrophage colony-stimulating factor receptor and reconstitution of a high-affinity receptor complex. Proc Natl Acad Sci U S A 89(10):4295-4299.
134. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. 2007. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 18(2):226-232.
135. Peng RQ, Ding Y, Zhang X, Liao Y, Zheng LM, Zhang XS. 2012. A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma. Cancer Biol Ther 13(14):1443-1448.
136. Perugini M, Brown AL, Salerno DG, Booker GW, Stojkoski C, Hercus TR, Lopez AF, Hibbs ML, Gonda TJ, D'Andrea RJ. 2010. Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common beta-subunit. Blood 115(16):3346-3353.
137. Ponomarev ED, Shriver LP, Maresz K, Pedras-Vasconcelos J, Verthelyi D, Dittel BN. 2007. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol 178(1):39-48.
138. Raich-Regue D, Naranjo-Gomez M, Grau-Lopez L, Ramo C, Pujol-Borrell R, Martinez-Caceres E, Borras FE. 2012. Differential effects of monophosphoryl lipid A and cytokine cocktail as maturation stimuli of immunogenic and tolerogenic dendritic cells for immunotherapy. Vaccine 30(2): 378-387.
139. Redman BG, Chang AE, Whitfield J, Esper P, Jiang G, Braun T, Roessler B, Mule JJ. 2008. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother 31(6):591-598.
140. Roberge CJ, McColl SR, Larochelle B, Gosselin J. 1998. Granulocyte-macrophage colony-stimulating factor enhances EBV-induced synthesis of chemotactic factors in human neutrophils. J Immunol 160(5):2442-2448.
141. Rokhlin OW, Griebling TL, Karassina NV, Raines MA, Cohen MB. 1996. Human prostate carcinoma cell lines secrete GMCSF and express GM-CSF-receptor on their cell surface. Anticancer Res 16(2):557-563.
142. Rosas M, Gordon S, Taylor PR. 2007. Characterisation of the expression and function of the GM-CSF receptor alpha-chain in mice. Eur J Immunol 37(9):2518-2528.
143. Rosenberg SA, Lotze MT. 1986. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol 4:681-709.
144. Roth L, Macdonald JK, McDonald JW, Chande N. 2011. Sargramostim (GM-CSF) for induction of remission in Crohn's disease. Cochrane Database Syst Rev (11):CD008538.
145. Roth L, MacDonald JK, McDonald JW, Chande N. 2012. Sargramostim (GM-CSF) for induction of remission in Crohn's disease: a cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials. Inflamm Bowel Dis 18(7):1333-1339.
146. Rowin J, Thiruppathi M, Arhebamen E, Sheng J, Prabhakar BS, Meriggioli MN. 2012. Granulocyte macrophage colonystimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve 46(3):449-453.
147. Rubtsov YP, Rudensky AY. 2007. TGFbeta signalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol 7(6):443-453.
148. Rutella S, Bonanno G, Pierelli L, Mariotti A, Capoluongo E, Contemi AM, Ameglio F, Curti A, De Ritis DG, Voso MT, Perillo A, Mancuso S, Scambia G, Lemoli RM, Leone G. 2004. Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha. Eur J Immunol 34(5):1291-1302.
149. Rutella S, Danese S, Leone G. 2006. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 108(5): 1435-1440.
150. Rutella S, Lemoli RM. 2004. Regulatory T cells and tolerogenic dendritic cells: from basic biology to clinical applications. Immunol Lett 94(1-2):11-26.
151. Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, Sene D, Cacoub P, Klatzmann D. 2011. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 365(22):2067-2077.
152. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75(2):253-261.
153. Sakagami T, Beck D, Uchida K, Suzuki T, Carey BC, Nakata K, Keller G, Wood RE, Wert SE, Ikegami M, Whitsett JA, Luisetti M, Davies S, Krischer JP, Brody A, Ryckman F, Trapnell BC. 2010. Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am J Respir Crit Care Med 182(1):49-61.
154. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, Hodi FS, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G. 2003. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 21(4):624-630.
155. Sebastian C, Serra M, Yeramian A, Serrat N, Lloberas J, Celada A. 2008. Deacetylase activity is required for STAT5-dependent GM-CSF functional activity in macrophages and differentiation to dendritic cells. J Immunol 180(9): 5898-5906.
156. Seki N, Sudo Y, Yoshioka T, Sugihara S, Fujitsu T, Sakuma S, Ogawa T, Hamaoka T, Senoh H, Fujiwara H. 1988. Type II collagen-induced murine arthritis. I. Induction and perpetuation of arthritis require synergy between humoral and cellmediated immunity. J Immunol 140(5):1477-1484.
157. Serafini P, Borrello I, Bronte V. 2006. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16(1): 53-65.
158. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. 2004. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64(17):6337-6343.
159. Shachar I, Karin N. 2013. The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications. J Leukoc Biol 93(1): 51-61.
160. Sheng JR, Li L, Ganesh BB, Vasu C, Prabhakar BS, Meriggioli MN. 2006. Suppression of experimental autoimmune myasthenia gravis by granulocyte-macrophage colony-stimulating factor is associated with an expansion of FoxP3 + regulatory T cells. J Immunol 177(8):5296-5306.
161. Sheng JR, Li LC, Ganesh BB, Prabhakar BS, Meriggioli MN. 2008. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis. Clin Immunol 128(2): 172-180.
162. Sheng JR, Muthusamy T, Prabhakar BS, Meriggioli MN. 2011. GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis. J Neuroimmunol 240-241: 65-73.
163. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Cohen LK, Mulligan RC, Dranoff G. 1998. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 95(22): 13141-13146.
164. Sonderegger I, Iezzi G, Maier R, Schmitz N, Kurrer M, Kopf M. 2008. GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J Exp Med 205(10):2281-2294.
165. Steinman RM, Hawiger D, Nussenzweig MC. 2003. Tolerogenic dendritic cells. Annu Rev Immunol 21:685-711.
166. Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E, Matsuyama T, Schmits R, Simard JJ, Ohashi PS, Griesser H, et al. 1995. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 268(5216): 1472-1476.
167. Takaki S, Kanazawa H, Shiiba M, Takatsu K. 1994. A critical cytoplasmic domain of the interleukin-5 (IL-5) receptor alpha chain and its function in IL-5-mediated growth signal transduction. Mol Cell Biol 14(11):7404-7413.
168. Takazoe M, Matsui T, Motoya S, Matsumoto T, Hibi T, Watanabe M. 2009. Sargramostim in patients with Crohn's disease: results of a phase 1-2 study. J Gastroenterol 44(6): 535-543.
169. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, Piccirillo CA, Salomon BL, Bluestone JA. 2008. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28(5): 687-697.
170. Tazawa R, Inoue Y, Arai T, Takada T, Kasahara Y, Hojo M, Ohkouchi S, Tsuchihashi Y, Yokoba M, Eda R, Nakayama H, Ishii H, Nei T, Morimoto K, Nasuhara Y, Ebina M, Akira M, Ichiwata T, Tatsumi K, Yamaguchi E, Nakata K. 2014. Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy. Chest 145(4): 729-737.
171. Thiruppathi M, Rowin J, Li Jiang Q, Sheng JR, Prabhakar BS, Meriggioli MN. 2012. Functional defect in regulatory T cells in myasthenia gravis. Ann N Y Acad Sci 1274:68-76.
172. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E, Schuler G. 1999. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190(11):1669-1678.
173. Tsuchiya Y, Igarashi M, Suzuki R, Kumagai K. 1988. Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells. J Immunol 141(2):699-708.
174. van de Laar L, Coffer PJ, Woltman AM. 2012. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood 119(15):3383-3393.
175. van Nieuwenhuijze A, Koenders M, Roeleveld D, Sleeman MA, van den Berg W, Wicks IP. 2013. GM-CSF as a therapeutic target in inflammatory diseases. Mol Immunol 56(4):675-682.
176. Vasu C, Dogan RN, Holterman MJ, Prabhakar BS. 2003. Selective induction of dendritic cells using granulocyte macrophage-colony stimulating factor, but not fms-like tyrosine kinase receptor 3-ligand, activates thyroglobulin-specific CD4 +/CD25 + T cells and suppresses experimental autoimmune thyroiditis. J Immunol 170(11):5511-5522.
177. Venkateshiah SB, Yan TD, Bonfield TL, Thomassen MJ, Meziane M, Czich C, Kavuru MS. 2006. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Chest 130(1):227-237.
178. Verginis P, Li HS, Carayanniotis G. 2005. Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4 + CD25 + T cells. J Immunol 174(11):7433-7439.
179. Verreck FA, de Boer T, Langenberg DM, Hoeve MA, Kramer M, Vaisberg E, Kastelein R, Kolk A, de Waal-Malefyt R, Ottenhoff TH. 2004. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci U S A 101(13):4560-4565.
180. Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupe P, Barillot E, Soumelis V. 2008. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 9(6):650-657.
181. Vu MD, Xiao X, Gao W, Degauque N, Chen M, Kroemer A, Killeen N, Ishii N, Li XC. 2007. OX40 costimulation turns off Foxp3 + Tregs. Blood 110(7):2501-2510.
182. Walker F, Nicola NA, Metcalf D, Burgess AW. 1985. Hierarchical down-modulation of hemopoietic growth factor receptors. Cell 43(1):269-276.
183. Walter MR, Cook WJ, Ealick SE, Nagabhushan TL, Trotta PP, Bugg CE. 1992. Three-dimensional structure of recombinant human granulocyte-macrophage colony-stimulating factor. J Mol Biol 224(4):1075-1085.
184. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, Kuchroo VK, Hafler DA. 2008. IL-21 and TGFbeta are required for differentiation of human T(H)17 cells. Nature 454(7202):350-352.
185. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL. 2001. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61(3):842-847.
186. Zhan Y, Lieschke GJ, Grail D, Dunn AR, Cheers C. 1998. Essential roles for granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF in the sustained hematopoietic response of Listeria monocytogenes-infected mice. Blood 91(3):863-869.
187. Zhan Y, Vega-Ramos J, Carrington EM, Villadangos JA, Lew AM, Xu Y. 2012. The inflammatory cytokine, GM-CSF, alters the developmental outcome of murine dendritic cells. Eur J Immunol 42(11):2889-2900.